The Cooley’s Anemia Foundation (CAF) announced that is accepting applications from individuals with thalassemia for the 2016 CAF-ApoPharma Distinguished Scholar Award. The CAF-ApoPharma Distinguished Scholar Award, which was established in 2014, is made possible through a grant from pharmaceutical manufacturer ApoPharma.
CAF will award up to two scholarships to a U.S. citizen(s) with a clinically significant form of thalassemia pursuing doctoral studies in biomedical sciences, including medicine, pharmacy, nursing and basic research. (Ph.D., M.D., D.D.S., Pharm.D., D.V.M, etc.) in the United States or abroad. Total annual funding available for the awards is $20,000. Students enrolled in a doctoral program for the fall of 2016 are eligible to apply. A clinically significant form of thalassemia would include alpha thalassemia major, beta thalassemia major, beta thalassemia intermedia, e beta thalassemia, hemoglobin H disease, or hemoglobin H disease-Constant Spring.
Applications must be received at CAF by September 30, 2016.
More information: CAF website